Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Testis-sparing surgery for small testicular masses: Functional and oncological outcomes.

Urologic oncology·2026

Same author

Hepatotoxic and nephrotoxic effects of etoxazole in rats: dose-response relationships, oxidative stress mechanisms, and provisional NOAEL/LOAEL estimates.

Toxicology mechanisms and methods·2026

Same author

Effects of Ethanolic Lyophilized and Nanoparticle Extracts of Cilo Wormwood (Artemisia haussknechtii Boiss.) Leaves on Histopathological Findings Antioxidant Defence System and Serum Biomarker Constituents in Diabetic Rats.

Applied biochemistry and biotechnology·2026

Same author

Evaluation of the quality of life among caregivers of cancer patients.

BMJ supportive & palliative care·2026

Same author

Correction: Immunoinformatics-driven multi-epitope vaccine design targeting PSMA, STEAP1, and B7H3 for prostate cancer.

Frontiers in medicine·2026

Same author

Design, Synthesis and Molecular Modeling Studies of Triazole Derivatives as Aromatase İnhibitors.

Chemical biology & drug design·2026

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Erectile dysfunction in successfully treated lymphoma patients.

Sercan Aksoy¹, Hakan Harputluoglu, Saadettin Kilickap

¹Department of Medical Oncology, Institute of Oncology, Hacettepe University, Sihhiye, Ankara, Turkey. saksoy07@yahoo.com

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer

|July 31, 2007

Summary

A significant majority of lymphoma survivors experience erectile dysfunction (ED). This study found 61% of men had ED, regardless of lymphoma type or hormonal changes, highlighting a need for clinical awareness and treatment options.

Related Experiment Videos

Last Updated: Jul 13, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Oncology
Urology
Endocrinology

Background:

Limited data exists on male sexual function in lymphoma survivors.
Assessing male sexual function and serum gonadotropins in treated lymphoma patients is crucial.

Purpose of the Study:

To evaluate the prevalence and severity of erectile dysfunction (ED) in lymphoma survivors.
To investigate the relationship between serum gonadotropins and ED in this population.

Main Methods:

A cohort of 59 male patients treated for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL) with chemotherapy and/or radiotherapy were assessed.
The International Index of Erectile Function (IIEF) was used to score erectile function.
Serum gonadotropin levels (follicle-stimulating hormone, luteinizing hormone) and testosterone were measured.

Main Results:

61.0% of lymphoma survivors reported some degree of ED (IIEF score < 26).
ED prevalence and severity were similar between HL and NHL patients and not correlated with age.
Hormonal abnormalities, including elevated FSH/LH and low testosterone, were observed in a subset of patients but did not correlate with ED presence or severity.

Conclusions:

Erectile dysfunction is highly prevalent in male lymphoma survivors, affecting over 60% of patients.
Clinicians must recognize ED as a significant issue in this population.
Awareness and provision of adequate treatment options for ED are recommended for lymphoma survivors.